文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

分次清髓性白消安用于老年或合并症患者异基因干细胞移植

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
PubMed 文献 · Blood Adv · 2023-01-01

该2期试验纳入78例接受相合亲缘或无关供者异基因造血细胞移植的成人血液肿瘤患者,采用延长给药的分次清髓性白消安方案,主要终点为第100天非复发死亡。中位随访36.4个月,第100天、1年、3年非复发死亡率分别为3.8%、8%、9.3%,年龄或HCT-CI评分间无显著差异,3年总生存80%。

要点

  • 延长分次清髓性白消安方案第100天非复发死亡率为3.8%
  • 1年与3年复发率分别为10%与18%,3年总生存80%
  • 年龄>60岁与<60岁、HCT-CI≥3与<3者非复发死亡及总生存均无显著差异

核心结论

  • 作者认为,分次清髓性白消安方案非复发死亡率低、未增加复发率,在老年或合并症患者中亦获得有前景的生存。

研究设计与样本

  • 2期试验纳入78例接受相合亲缘或无关供者异基因造血细胞移植的成人血液肿瘤患者,方案为门诊第-20天和第-13天白消安80 mg/m²,第-6至-3天氟达拉滨40 mg/m²,随后白消安按全疗程目标曲线下面积20 000 mol/min给药,主要终点为第100天非复发死亡。

主要发现

  • 中位年龄61岁(范围39-70岁),急性白血病占24%、骨髓增生异常综合征占27%、骨髓增殖性疾病/慢性髓性白血病占44%,HCT特异性合并症指数≥3者34例(44%)。
  • 中位随访36.4个月(范围2.9-51.5),第100天、1年、3年非复发死亡率分别为3.8%、8%、9.3%,年龄或HCT-CI评分间无显著差异。
  • 1年与3年复发率分别为10%与18%;3年总生存80%,年龄或HCT-CI评分间无显著差异,年龄>60岁与<60岁、HCT-CI≥3与<3者相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditional conditioning regimens for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and those with comorbidities. We hypothesized that a fractionated myeloablative busulfan dose delivered over an extended period would reduce nonrelapse mortality (NRM) while retaining antileukemic effects. Here, we performed a phase 2 trial for adults with hematological malignancies receiving matched related or unrelated allo-HCT. Participants received busulfan 80 mg/m2 as outpatients on days -20 and -13 before transplant. Fludarabine 40 mg/m2 was administered on days -6 to -3, followed by busulfan dosed to achieve a target area under the curve of 20 000 mol/min for the whole course. The primary end point was day-100 NRM. Seventy-eight patients were included, with a median age of 61 years (range, 39-70 years), who received transplantation for acute leukemia (24%), myelodysplastic syndrome (27%), or myeloproliferative disease/chronic myeloid leukemia (44%). HCT-specific comorbidity index (HCT-CI) was ≥3 in 34 (44%). With a median follow-up of 36.4 months (range, 2.9-51.5), the 100-day, 1-year, and 3-year NRM rates were 3.8%, 8%, and 9.3%, respectively, without a significant difference in age or HCT-CI score. The 1-year and 3-year relapse incidence was 10% and 18%, respectively. The 3-year overall survival was 80%, without a significant difference in age or HCT-CI score and was similar for patients aged >60 years and those aged <60 years as well as for those with HCT-CI ≥3 and HCT-CI <3. Overall, a myeloablative fractionated busulfan regimen has low NRM without an increase in relapse rate, resulting in promising survival, even in older patients or in patients with comorbidities. This trial was registered at www.clinicaltrials.gov as #NCT02861417.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Popat UR, Pasvolsky O, Bassett R, et al. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023. PMID: 37611156. doi:10.1182/bloodadvances.2023010850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。